论文部分内容阅读
目的总结探讨肿瘤系列(CA125、CA199、CEA)在血清中含量对于诊断卵巢癌的临床意义。方法收集23例卵巢癌患者及23例身体健康的志愿者的血清,采用电化学发光免疫分析法检测2组人员血清里上述3种肿瘤标志物的含量,并进行统计分析。结果卵巢癌患者血清中CA125、CA199及CEA水平明显高于身体健康的志愿者(P<0.05)。卵巢癌组CA125阳性检出率为72.3%,CA199阳性检出率为43.1%,CEA阳性检出率为20.2%。CA125+CA199阳性检出率为86.1%,CA125+CA199+CEA阳性检出率为90.8%。结论肿瘤系列可作为诊断卵巢癌的敏感指标应用到临床中,为卵巢癌的早期诊断和治疗提供重要参考。
Objective To summarize the clinical significance of the serum levels of tumor series (CA125, CA199, CEA) in the diagnosis of ovarian cancer. Methods Serum samples of 23 patients with ovarian cancer and 23 healthy volunteers were collected. The levels of these three tumor markers in serum of two groups were detected by electrochemiluminescence immunoassay and analyzed statistically. Results Serum levels of CA125, CA199 and CEA in patients with ovarian cancer were significantly higher than those in healthy volunteers (P <0.05). In ovarian cancer group, the positive rate of CA125 was 72.3%, the positive rate of CA199 was 43.1%, and the positive rate of CEA was 20.2%. The positive rate of CA125 + CA199 was 86.1%, and the positive rate of CA125 + CA199 + CEA was 90.8%. Conclusion The tumor series can be used as a sensitive indicator in the diagnosis of ovarian cancer in clinical practice, providing an important reference for the early diagnosis and treatment of ovarian cancer.